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Abstract: DNA delivery is at the forefront of current research efforts in gene therapy and synthetic
biology. Viral vectors have traditionally dominated the field; however, nonviral delivery systems
are increasingly gaining traction. Baculoviruses are arthropod-specific viruses that can be easily
engineered and repurposed to accommodate and deliver large sequences of exogenous DNA into
mammalian cells, tissues, or ultimately organisms. These synthetic virus-derived nanosystems (SVNs)
are safe, readily customized, and can be manufactured at scale. By implementing clustered regularly
interspaced palindromic repeats (CRISPR) associated protein (CRISPR/Cas) modalities into this
system, we developed SVNs capable of inserting complex DNAs into genomes, at base pair precision.
We anticipate a major role for SVNs as an attractive alternative to viral vectors in accelerating genome
engineering and gene therapy applications in the future.
Keywords: baculovirus; CRISPR; gene editing; genome engineering; precision DNA docking
1. Introduction
Programmable DNA nucleases such as clustered regularly interspaced palindromic repeats
(CRISPR) associated protein 9 (CRISPR/Cas9) have enormously contributed to rejuvenate and
democratize the gene editing and gene therapy fields thanks to their efficiency, cost-effectiveness,
and specificity, in a variety of model organisms in ex vivo and in vivo. Although CRISPR system was
originally discovered in bacteria as a previously unknown adaptive immune response pathway,
it was successfully repurposed into a gene editing tool when Cas9, an RNA guided DNA
programmable nuclease, was shown to efficiently work in mammalian cells to produce double
stranded DNA breaks (DSBs) at desired genomic loci with very high efficiency and little off-target
effects [1,2].
According to the subsequent DNA repair mechanism, Cas9-induced DSBs can be resolved with
the production of small insertion/deletions (indels) through the non-homologous end joining (NHEJ)
DNA repair pathway, or precise gene editing outcomes when the homology-directed repair (HDR)
pathway is exploited in combination with a suitable DNA template [2].
Remarkably, the applications of CRISPR technology extends beyond gene editing and catalytically
inactive Cas9 has been successfully used, in fusion with various cofactors, to modulate gene
expression [3], visualize single genomic loci in living cells [4], and change the epigenetic state
of a given chromatin region [5].
As the first clinical trials involving CRISPR are being undertaken, significant effort is invested
to fully transform this powerful gene editing tool into a reliable technology for next generation gene
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therapy interventions ranging from immunization and cancer therapy to gene replacement in vivo.
More efficient Cas9 variants with fewer off-target effects have been engineered, and the extensive
search for Cas variants and Cas-like proteins has led to the discovery of additional endonucleases
which further expand the repertoire of targetable DNA sequences [6–8].
While CRISPR-mediated gene editing is highly efficient in “easy to transfect” cell lines, its efficiency
drops sharply when switching to transfection recalcitrant cell lines, exacerbated when a DNA template
has to be co-transfected in addition to guide RNA and Cas9 to achieve homology-directed repair.
Delivering Cas9, sgRNA, and donor DNA simultaneously within the same cell and with the appropriate
stoichiometric ratio remains a formidable challenge, often resulting in no editing events or the
production of indels. Coupled with the cell cycle dependency of the HDR pathway and its context
dependent activity [9], delivery efficiency represents an imposing roadblock to the development of
future highly efficient CRISPR-based gene therapy interventions.
Nonviral delivery systems (e.g., electroporation, polymer-based, or lipid-based delivery of RNA,
DNA, and proteins) can achieve remarkable editing efficiencies in cultured cells [10], however, at the
expense of time-consuming parameter adaptation and at times toxic side effects at the cellular level [10].
Promisingly, lipid-based delivery of Cas9/sgRNA ribonucleoprotein (RNP) complexes can be harnessed
in vivo to achieve gene knockouts, albeit with lower editing efficiency than in cultured cells [11–13].
Common bottlenecks to consider for nonviral delivery systems are scalability and manufacturing
costs [14]. These technologies, although extremely safe, would likely continue to be confined to ex vivo
gene editing, for which parameters such as cell confluency and culturing methods could be adjusted in a
more straight-forward manner to achieve the highest delivery and gene editing efficacies. Furthermore,
to the best of our knowledge, in vivo lipid-based delivery of RNPs has not been demonstrated to date
for precise gene editing approaches in which concomitant delivery of a DNA donor is required.
In marked contrast, currently available, both ex vivo and in vivo, viral delivery
systems (e.g., lentivirus, adenovirus, or adeno-associated viruses) are characterized by high
transduction efficiency. However, pre-existing immune response in humans, undesired integration at
CRISPR-produced DSBs [15] or randomly in the genome, impede their future applications as systemic
gene delivery vectors. In addition, viral vector applications are constrained by their limited cargo
capacity which is typically derived from the defined and invariable geometry of their viral capsids,
forcing researchers to adopt alternative approaches such as splitting the CRISPR machinery across
several virions, combined with using smaller Cas variants [16], split-intein lentiviral vectors (LV) [17],
or multiple adeno-associated vectors (AAVs) [18], adding an entire layer of new stochastic challenges
to the desired gene editing outcome.
At the boundary between viral and nonviral CRISPR delivery systems, emerges a third highly
attractive option which is the use of baculoviral delivery vectors engineered from the Autographa
californica multiple nucleopolyhedrovirus (AcMNPV). Baculoviral vectors (BVs) are technically viruses
in narrowly defined arthropod hosts which have the unique advantage that they do not replicate
in mammalian cells but can be easily engineered to efficiently transduce them. In this context,
they are replication and integration deficient (alike nonviral delivery systems), while preserving
a high transduction rate (alike viral delivery systems) together with a cost-effective and scalable
manufacturing process. Synthetic virus-derived nanosystems (SVNs), in this respect, combine the best
of both delivery system approaches.
Importantly, the baculoviral genome is characterized by a very large heterologous DNA
cargo capacity, far superior to LVs, adenovirus (AV), and AAVs, due to a flexible viral envelope
which simply grows when additional heterologous DNA is inserted [15–17]. Thus, baculoviral vectors
are uniquely suited to accommodate all components of a CRISPR machinery on a single vector [19,20],
rendering them highly suitable for both ex vivo and in vivo delivery, taking advantage of customizable
tropism and the lack of pre-existing immune response in humans [21]. In this review, we discuss
baculoviral delivery systems and how current vector systems can be converted, through genome
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engineering and pseudotyping, into bona fide synthetic viral nanosystems (SVNs) to enable the
deployment of CRISPR toolkits in next-generation gene editing and genome engineering applications.
2. MultiBac Baculovirus Engineering
Baculoviridae are a family of enveloped dsDNA viruses with invertebrate host specificity. In nature,
the genome of baculoviruses ranges between 80 and 180 kb. One of the most studied and translationally
relevant members of the family is the Autographa californica multiple nucleopolyhedrovirus (AcMNPV)
with a genome of ~135 kb encompassing 155 open reading frames (ORFs). The AcMNPV life cycle
involves two viral forms that contain the same genetic information, which occupy distinct subcellular
localization and serve different purposes. Budded viruses (BV) are enveloped virions which are
constantly produced by infected cells, whereas occlusion-derived virions (ODVs) are highly structured
viral forms organized in a matrix of polyhedrin proteins which shield the virions from adverse
conditions such as cell death, desiccation, and thermolability, serving as an effective viral reservoir [22].
Although both viral forms play crucial roles during primary and secondary infections stages, ODVs are
not required for viral propagation in laboratory culture and the polyhedrin protein can be removed
from the AcMNPV genome. This leads to ablation of ODV production and does not affect budded
virions, which are released directly into the culture media of AcMNPV infected cells (typically from
Spodoptera frugiperda, Trichoplusia ni or Bombyx mori) (Figure 1).
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large single copy plasmid called bacmid [23]. In the presence of a helper plasmid expressing the 
components of the Tn7 transposition machinery, a DNA insert can be shuttled into the bacmid into 
the Tn7 attachment site disrupting LacZα in blue/white screening. Then, the bacmid is isolated from 
Escherichia coli and introduced by transfection into insect cells to produce recombinant baculovirus 
expressing the protein of interest. The original system utilizing this approach, Bac-to-Bac (Invitrogen), 
has been extensively used for protein production in insect cells, usually coupled to strong viral 
promoters such as p10 or polh driving the expression of the protein of interest. 
Alternatively, when these viral promoters are substituted for mammalian promoters (e.g., 
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heterologous expression in mammalian cells, with little to no cytotoxic effect [21]. Importantly, 
Figure 1. ild-type Autographa californica multiple nucleopolyhedrovirus (Ac NP) produces two
viral forms. Occlusion-derived viruses (ODVs) are found in occlusion bodies, embedded in protein
matrixes mostly composed of polyhedrin protein. Budded viruses (BVs) are constantly released in the
culturing media as rod-shaped particles surrounded by an envelope equipped with viral glycoprotein
such as GP64, essential for BVs entry into target cells.
This finding allowed for the generation of AcMNPV genomes in which the polyhedrin protein
locus is substituted for an F replicon, a mini Tn7 attachment site within a LacZα gene, and a kanamycin
resistance marker. The resulting 135 kb AcMNPV genome is propagated in bacteria as a large single
copy plasmid called bacmid [23]. In the presence of a helper plasmid expressing the components of the
Tn7 transposition machinery, a DNA insert can be shuttled into the bacmid into the Tn7 attachment
site disrupting LacZα in blue/white screening. Then, the bacmid is isolated from Escherichia coli and
introduced by transfection into insect cells to produce recombinant baculovirus expressing the protein
of interest. The original system utilizing this approach, Bac-to-Bac (Invitrogen), has been extensively
used for protein production in insect cells, usually coupled to strong viral promoters such as p10 or
polh driving the expression of the protein of interest.
Alternatively, when these viral promoters are substituted for mammalian promoters
(e.g., cytomegalovirus (CMV) promoter), the budded virions have also been shown to efficiently
drive heterologous expression in mammalian cells, with little to no cytotoxic effect [21]. Importantly,
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baculoviral promoters are inactive in mammalian cells, rendering virus replication deficient and also
integration deficient. Work involving baculoviruses is considered to be safe for users with the lowest
biosafety level requirement (BSL-1) in most countries [19,21]. A variety of mammalian cells, including
primary cell lines, have been efficiently transduced by baculovirus pseudotyped with glycoproteins
from mammalian viruses, typically vesicular stomatitis virus (VSV) in a “BacMam” approach [24] with
customized transfer plasmid, genetically encoded fluorescent probes, and cell-based assays available
as off-the-shelf reagents.
The original BacMam approach mostly followed the one gene one vector paradigm. To fully
take advantage of the superior cargo capacity of the baculoviral genome [20], diverse modalities
of DNA assembly and insertion were developed and implemented in our laboratory giving rise
to the MultiBac system, originally conceived to produce large multiprotein complexes with many
subunits in insect cells [25]. We described the technical aspects of MultiBac and its exploits in
detail previously [26–28]. Therefore, here, we focus only on key features relevant to mammalian
multigene delivery, ultimately for CRISPR-mediated gene editing and genome engineering.
MultiBac relies on in vitro controlled Cre-mediated recombination, a collection of bacterial
antibiotic resistance markers, and a conditional replicon for efficient assembly of multigene transfer
plasmid which can be readily shuttled into a custom-engineered baculovirus genome, primarily by Tn7
transposition (Figure 2). Following standard procedures, the resulting composite bacmid is extracted
and used to transfect insect cells for producing large quantities of the virus. Within insect cells,
the recombinant bacmid behaves as a naked DNA virus, and triggers viral amplification without the
need for helper or packaging vectors in contrast to other viral systems. The budded virions, which are
constantly released into the medium, are typically amplified for one to two passages up to titers as
high as 1 × 108–1 × 109 plaque forming units per ml (pfu/mL) (Figure 2).
Next, the virus containing supernatant is cleared by low-speed centrifugation and filtration to
remove insect cells and debris and, if needed, can be further concentrated by high-speed centrifugation
to obtain higher transduction efficiencies. In analogy to BacMam, a ”MultiBacMam” transduction of
mammalian cells is typically achieved between 4 and 6 h of exposure to the virions, while maximal
transgene expression levels are observed between 24 and 72 h post transduction (Figure 2). The MultiBac
system features a second Cre-LoxP entry site distal to the Tn7 attachment site which can be functionalized,
for example, with fluorescent proteins (e.g., EYFP, mCherry, etc.) to gauge viral titer during
amplification steps. Tropism, which in the viral context typically describes the viral means of
entry or host range, can also be modulated by exploiting this site, by introducing genes encoding for
envelope proteins from completely unrelated viral species. This process, known as pseudotyping,
results in the production of chimeric enveloped baculovirus which can then enter cells and even
organisms other than its original insect host.
Using this approach, simultaneous delivery of up to five different transgenes in a variety of
mammalian cell lines was achieved with high efficiency, including in cells recalcitrant to plasmid
transfection and primary cells [19] (Figure 2). Multiple fluorescently labelled proteins, reporters,
and cell-fate driving transcription factors have all been efficiently delivered to mammalian cells
for diverse applications ranging from in vivo cell imaging to trans-differentiation [19]. Little to no
cytotoxic effect was observed [25]. The latency of the transgene expressions and their persistence in the
host cells were transient and largely dependent on initial viral titers and cellular proliferation rates,
with the vectors being diluted over time, reminiscent of plasmid transfection [19]. This feature which
is commonly considered to be a handicap in traditional gene therapy approaches, can be, in fact,
extremely valuable for CRISPR-based approaches, in which Cas9 and sgRNAs expressions need to be
precisely controlled and, at some point, disposed of to avoid undesired gene editing outcomes.
In trend-setting experiments, the MultiBac-based approach was utilized to efficiently deliver, on a
single vector, all components required for precise gene editing in mammalian cells (Cas9, sgRNA,
and HDR donor), enabling C-terminal tagging of the HMGA1 gene locus with eGFP in cultured
mammalian cells as a proof-of-concept [19,20]. This result is already remarkable when compared with
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other delivery systems which typically require, for the same editing strategy, co-transduction with two
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transduction for simultaneous delivery and expression of four fluorescently labelled proteins.
(Assembly) In this example, four different genes of interests (GOIs: H2B iRFP720, EYFP tubulin,
mTFP1 actin, and mito-mCherry) are cloned into pACEMam1, p DK, pMDC, and pMDS, respectively.
Through in vitro controlled Cre-mediated recombination, the 4 plasmids are assembled into a
unique vector; (Transfer) The all-in-one vector can now be transformed into DH10beta MultiBac
cells which contain the MultiBac genome, outfitted with the Bac-to-Bac locus, and helper plasmid
expressing the Tn7 transposase proteins. White bacterial colonies are expanded and cultured to extract
the recombinant bacmid DNA; (Amplification) The bacmid DNA is transfected into insect cells (Sf21,
Sf9, or Hi5) for the initial stage of virus production. After a few days, the supernatant, containing
low titer viral concentration, is used to inoculate fresh cells to obtain high viral titers and the virus
containing supernatant is harvested; (Transduction) The virus containing supernatant can be readily
used for mammalian cell transduction, or further concentrated by ultracentrifugation to achieve higher
transduction efficiencies.
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3. Homology-Directed Repair (HDR), Base Editing, and Search-and-Replace Approaches
CRISPR/Cas9 technology enables highly efficient generation of DSBs at desired genome loci with
a programmable DNA nuclease guided by a single guide RNA (sgRNA). The sgRNA is a chimeric
fusion of CRISPR-associated RNA (crRNA) and trans-activator CRISPR-associated RNA (tracrRNA) [1],
and its spacer sequence (e.g., the portion of the sgRNA complimentary to its genomic target) can be
designed to match the desired genomic target (protospacer), providing that the latter is followed by a
short protospacer adjacent motif (or PAM). The PAM requirement typically depends on the Cas9 variant
being used (e.g., NGG for Steptococcus pyogenes Cas9 or NNGRRN for Staphylococcus aureus Cas9 [8])
and constrains the genomic area of intervention. To expand the universe of the “editable” genome,
different Cas9 variants, or other CRISPR systems such as Cas12a [7], CasX [29], or engineered enzymes
with altered PAM specificity [8] can be implemented. Online platforms for CRISPR experimental
designs can easily design sgRNA candidates which are scored based on their sequence composition,
PAM, and number of potential off-targets also implementing scores obtained from high-throughput
validation studies where available [30].
Upon successful delivery, the Cas9/sgRNA complex binds to its target region and produces a
blunt double stranded break at 3–4 bases upstream of the PAM sequence. Again, different Cas enzymes
can produce slightly different DSB outcomes which vary for blunt/staggered ends or relative position
to the PAM. For instance, Cas12a cleaves the DNA at 18 bp distance from its -NTT PAM, leaving a five
nucleotides staggered DSB [7].
Once the DSB has been produced, endogenous DNA repair pathway components are recruited to
repair the DNA damage and influence the gene editing outcome. The non-homologous end joining
(NHEJ) pathway is the most efficient DNA repair mechanisms in most cell types and it is constitutively
active at all cell cycle stages [9]. Although the NHEJ pathway is referred to as an “error-prone”
DNA repair pathway, most of the Cas9-induced DSBs are presumably repaired seamlessly [31],
restoring protospacer and PAM sequence creating a loop sequence of DSB induction and repair
cycles. Eventually, the NHEJ pathway introduces mutations (usually small insertions and deletions),
which alter the protospacer sequence enough to block Cas9-mediate cleavage (Figure 3). Indels can be
useful for introducing frameshift mutations and efficiently interrupting gene functions ex vivo but,
due to their unpredictability, this approach is not likely to be translated into any in vivo therapy.
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Alternatively, DSB can also be repaired through homology-directed repair (HDR) DNA
repair pathway. Unlike the NHEJ pathway, the HDR pathway takes advantage of a DNA template which,
in virtue of homology arms surrounding a novel DNA fragment, faithfully introduces the new
information within the host genome (Figure 3). HDR activity, however, is typically low and cell cycle
regulated; mainly confined to the late S and G2 phases [32].
Several strategies have been applied to enhance CRISPR-HDR efficiency ranging from DNA
repair pathway modulation to Cas9 variants engineering. NHEJ inhibiting strategies, using small
molecule inhibitors of ligase IV such as SCR7, have been shown to nearly double the efficiency of the
HDR pathway [33]. Similarly, p53 inhibition to down-tune DNA damage response [34] or expression
of engineered ubiquitin inhibitors of 53BP1 [35] (a mediator of end-resection pathway) managed to
slightly increase HDR efficiency.
Albeit extremely interesting, it is worth reminding that modulation of the HDR and NHEJ pathways
may not be advantageous in vivo, because modulating vital DNA damage response pathways could
result in the production of undesired and potentially deleterious long-lasting side effects such as de
novo mutations or genomic aberrations. Another interesting and less invasive approach to increase
HDR-mediated integration is taking advantage of Cas9 variants engineered to be more stable during
cell cycle stages in which the HDR pathway is naturally more active. One such approach utilizes a Cas9
C-terminally fused with a fragment from geminin proteins (derived from the FUCCI cell cycle reporter
system [36]) which favors Cas9 accumulation in S/G2 and nearly doubles gene editing efficiency [37].
Similarly, ABT and nocodazole, two inhibitors of microtubule polymerization, have been used to
reversibly arrest cell cycle in G2/M phases to enhance CRISPR/HDR-mediated gene editing in human
pluripotent stem cells (hPSCs) [38].
Remarkably, higher HDR efficiencies can be achieved by using optimized nonviral delivery
systems even in the absence of further Cas9 engineering or HDR/NHEJ ratio manipulation. Roth and
colleagues implemented an optimized nonviral delivery electroporation system of Cas9/sgRNAs
RNPs complexes and single-stranded oligonucleotide donors (ssODN) templates in cultured cells and
obtained up to 60% correct integration and simultaneous knock-in in up to three different loci [10],
albeit at the expense of mild cytotoxicity (30% cell death) and relatively small insert size (700 bp
excluding the short homology arms). This approach has been successfully used to edit and engineer
TCR receptors in primary human T-cells [10] which are notoriously recalcitrant to transfection and
poorly transduced by most viral vectors. The positive impact of this delivery technology on the
increased HDR-mediated knock-in efficiency could probably be attributed to the high number of
ssODN delivered per cell but its translation in vivo would be extremely challenging.
The efficiency of CRISPR/Cas9 (and Cas variants) to induce DSBs is a double-edged sword.
Although overexpression of Cas9 results in higher editing efficiency, it can cause off-target cleavage and,
in the presence of a DNA donor, can lead to random (and undesired) genomic integration. Furthermore,
considering the diploid nature of the human genome, even in the presence of successful knock-in
or gene replacement, most cells contain one corrected allele and the other wild-type or, worse, are
randomly mutated with unpredictable effect on the protein production outcome. Edited cells ex vivo
can be easily screened for the absence of off-targets, undesired integrations, or homozygous knock-in
events, but the situation is totally different in vivo.
While the off-target problem can be partially dealt with by using more specific Cas9 variants such
as EvoCas9 [39] or Cas9-HF [40] and by improving the sgRNA design, the on-target repair outcomes
are again often resolved with random indels.
Given the inefficiency of HDR-based editing, combined with high off-target rates and the
unpredictability of the unwanted on-target repair events, alternative gene editing strategies based on
catalytically inactive programmable nucleases have been developed. Mutations in the RuvC 1 (D10A)
and HNH (H840A) domains of Cas9, respectively, abolish complimentary and non-complimentary
DNA strand cuts [1]. Cas9 D10A and Cas9 H840A are still able to bind the sgRNA and their DNA
target, but only produce the nicking of one DNA strand, whereas a combination of both mutations
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completely abolishes the enzymatic activity, resulting in a catalytically dead Cas9 (dCas9). When
fused to cytosine deaminase, dCas9 can work as a base editor (BE), resulting in single base changes
within the target sequence producing C•G to T•A conversion [41]. Additionally, the repertoire of base
editing possibilities has been expanded by the development of adenine base editors (ABEs), in which
Cas9(D10A) is coupled to an engineered adenine deaminase resulting in A•T to G•C conversions [42].
Remarkably, these approaches are more efficient than HDR-based editing as they do not rely on
endogenous DNA repair pathways and produce virtually no by-products because, in the absence of
successful editing, less than 0.1% indels are produced [42].
A more recent “search and replace” approach, named prime editing (PE), relies on Cas9 H840A
fused to the Moloney murine leukemia virus reverse transcriptase (MMLV-RT). Combined with an
engineered prime-editing sgRNA (PegRNA), the PE binds its target DNA and nicks one strand, whereas
the MMLV-RT domain creates a short cDNA using the nicked strand as primer and the PegRNA
as template. Then, the newly hybridized cDNA is processed by flap excision-ligation repair and
stably incorporated into the genome. The authors showed that PE can efficiently perform all 12 single
base substitutions and insert triplets with varying efficiencies and indel rates, mostly dictated by the
PegRNA design and the target locus [17]. Amongst the potential drawbacks of both BE and PE, are the
very limited size for the gene editing intervention (one to three base pairs for BE and −80, +44 base
pairs for PE) and the toxic effects of the associated enzymes at the cellular level. However, given their
superior efficiency (up to 75% editing with BE and 50% with ABE) [41,42] and their enhanced safety as
compared with DSB-editing approaches, base editors and search and replace approaches are more
promising than HDR-based strategies for single base corrections or codon substitutions with direct
implications for a variety of disease relevant genes mutations.
While no DNA template is required for DNA editors, larger Cas9 variants are required for both
BE (200 kDa, 5.4 kb) and PE (240 kDa, 6.3 kb) as compared with standard SaCas9 (130 kDa, 3.2 kb),
Cas12a (143 kDa, 3.8 kb) or SpCas9 (163 kDa, 4.2 kb).
Although there is no shortage of available strategies for precise gene editing, a careful evaluation
of efficiency versus safety must be undertaken in each experimental approach, together with the PAM
availability and with the final gene editing outcome desired (zygosity, toxicity of the undesired editing
events, etc.). Foreseeably, more approaches will be developed in the future to reduce off-targets and
undesired gene editing outcomes, while increasing efficiency and specificity. Nevertheless, all the
available (and presumably future) precise gene editing strategies, rely on the simultaneous delivery of
two or more molecular components, often of considerable sizes which challenges the cargo capacity
of most viral vectors. Nonviral deliver could possibly cope with the increasing size and number of
the required components, but at the expenses of cell-type optimization, manufacturing costs, and
being limited to ex vivo approaches in controlled environments for precise gene editing [10,11,13,43].
Baculovirus delivery vectors, on the contrary, can host an impressive cargo size and can efficiently
delivery all the examined gene editing approaches as all-in-one toolkits, maximizing the chance of
precise genomic intervention (Figure 4). In combination with the MultiBac DNA assembly technology,
baculovirus delivery vectors constitute an excellent modular platform for assembly and efficient
delivery of different CRISPR toolkits to mammalian cells.
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4. MultiBac and Clustered Regularly Interspaced Palindromic Repeats (CRISPR)
HDR-based CRISPR gene editing has already been implemented in BVs, leading to a substantial gain
in delivery efficiency of all-in-one vectors with modest improvements in gene editing efficiencies [19,20,44].
Although multiple strategies could be implemented to increase HDR efficiency, in the context of BVs,
they would take a heavy toll on vector engineering time and represent an unnecessary DNA cargo
burden which should be avoided for future in vivo applications.
Rather than forcing target cells to commit to HDR repair, the NHEJ pathway can be exploited to
produce targeted insertions in the absence of homology arms, by simply redesigning the donor
DNA template. As previously discussed, the NHEJ pathway is mistakenly referred to as an
“error-prone” DNA repair pathway. Indeed, Maresca and colleagues uncovered, in 2013, the previously
underestimated precision of the NHEJ repair pathway and, in combination with transcription
activator-like effector nucleases (TALEN) or zinc finger nucleases (ZFNs), used it to precisely integrate
up to 15 kb of DNA donors into mammalian cells through a technique called obligate ligation-gated
recombination (ObLiGaRe) [45].
The same holds for CRISPR-based approaches and, by slightly changing the design of the
donor DNA, NHEJ-based editing has been shown to efficiently produce knock-ins in dividing and
non-dividing cells at base pair precision. Furthermore, this strategy, named homology-independent
targeted integration (HITI), does not require ho ology arms and it works in vivo, producing up to
60% of correct editing [18,46–48].
HITI works by excising the donor DNA, exploiting the same Cas9 target site used for the genomic
destination locus. Upon cleavage, the donor is released and it is seamlessly ligated to seal the
genomic DSB. The orientation of the integrated donor should be random (50% forward and 50%
reverse) but Suzuki and colleagues showed that up to 98% of the integrations contained a forward
insertion [18,46]. Indeed, thanks to a clever sgRNAs design on the donor, the reverse integration
restored both flanking target sides and, if Cas9 and donor molecules were present, the locus was
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continuously edited through a “proofreading” activity. Consequently, forward integrations, in which
the sgRNAs targets were destroyed, were locked in place and immune from further editing (Figure 5).
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The self-cleaving nature of an HITI-based viral vector, would prevent the successful generation of
an all-in-one vector including Cas9, sgRNA, an donor module within mammalian cells (e.g., HEK293T).
In this case, indeed, the vector would be self-cleaved during viral packaging leading to the generation of
donor-free vectors capable only of inducing indels or severely impairing viral production and stability.
In baculovirus all-in-one vector, however, viral packaging within insect cells would be a strong
advantage as mammalian cell promoters are typically n t expressed in insect cells. This would
ens re that no Cas9 is expressed during viral packaging in Sf21 cells, preserving virions integrity and
delivering intact all-in-o e vectors.
In this regard, MultiBac could be repurposed to have a separate function in each one of the
donor/acceptor vectors (Cas9, sgRNA, HITI donor, fluorescence reporter, etc.) to ensure maximum
flexibility and modular design (Figure 6).
Furthermore, an attractive perspective in the gene editing field is the docking of a large DNA
fragment (>10 kb) at a single base position in the genome for exon or whole gene replacement or to
incorporate a new piece of genetic information to implement new cellular functions. This could include
whole synthetic gene regulatory networks, signaling pathways, or engineered enzymatic cascades.
The purposes of large DNA cargo insertions, at precise loci, span from gene therapy to synthetic
biology and industrial applications. Large cargo DNA docking, however, is a challenging task for most
CRISPR strategies, regardless of the delivery system. Although NHEJ-based approaches have already
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been used for large cargo docking of up to 15 kb [45], the efficiency in this case has been severely
limited by the delivery method. By combining HITI and MultiBac, in contrast, precise docking of large
DNA fragments could be readily implemented by repurposing Cre-mediated fusion to expand the
donor size of the all-in-one vectors, while maintaining high transduction efficiency.Pharmaceutics 2020, 12, x 11 of 21 
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Although HITI has been successfully used to correct disease-causing genes in vivo [46], despite the
high gene editing efficiency, it has to be noted that a consistent proportion of the alleles would still carry
on-target indels. HITI intervention generates a complex pattern of repair outcomes and zygosities
which must be carefully evaluated for each target before embarking into in vivo experiments because,
depending on the target gene, indels could result in aberrant phenotypes (Figure 7). To minimize
the side effects linked to DSBs productio in vivo, optimized strategies such as intron targeti g
or whole exon or gene replacement would be a visable, helping to reduce the unpre ictability of
undesired indels.
Importantly, MultiBac will be equally capable of accommodating and delivering base editors
and prime editing CRISPR-based t olkits. As previously discussed, these approaches, which rely
catalytically inactive or impaired Cas variants, are intrinsically safer in virtue of the lack of DSBs.
Despite the reduced number of components required for precise editing, base and prime editing
require larger engi eered Cas effectors, which significantly i crease the size of the all-in-one vectors
and cannot be efficiently delivered using a single AAV or lentiviral vector. However, this can be easily
assembled on baculoviral vectors (Figure 4) and efficiently delivered, preserving the same modularity
and strategy depicted in Figure 6. We foresee that base editors and prime editing, delivered through
all-in-one MultiBac vectors, should be a game changing technology suitable for in vivo applications in
virtue f superior safety, enhanced delivery efficiency, and seamless gene editing outcome with few to
no by-products.
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5. Challenges to Baculovirus Delivery In Vivo
When combined with CRISPR and homology-independent targeted integration, baculovirus
expression vectors engineered through MultiBac technology could potentially overcome many of the
issues imposed by standard viral vectors. While further studies are required to address safety and
efficacy of baculovirus delivery in vivo, key potential challenges have been addressed (summarized in
Table 1). Despite wild-type virus life cycle being well characterized, the features that regulate baculoviral
transduction in mammalian cells, from entry to innate immune response, have remained elusive.
It is well known that BV transduction efficiency, despite being often high, is pronouncedly cell-type
dependent and there are certain cell types which are poorly or ineffectively transduced. A key
aspect has been addressed by studying the entry route of BVs in mammalian cells. The entry of
wild-type AcMNPV into insect and mammalian cells is mediated by binding of the major envelope
glycoprotein GP64 to the host cell surface. GP64 is an essential component of budded virions, which is
not only involved in cell-to-cell transmission [49] but is also required for viral budding from insect
cells [50]. Although the nature of the interactions of GP64 with specific membrane receptors is unclear,
efficient entry of budded viruses has been shown to be low-pH and cholesterol dependent [51,52].
Similar to most enveloped viruses, clathrin-dependent endocytosis seems to be the main process
involved in baculovirus internalization in mammalian cells, together with macropinocytosis [51,53].
In the endosomes, acidification triggers GP64-mediated membrane fusion, which results in the release
of the viral nucleocapsid into the cytoplasm [54,55]. Studies have revealed that capsids are actively
transported towards the nuclear compartment via polymerization of actin filaments and enter the
nucleus through the nuclear pore complex [56,57]. In addition to rationally designed protein fusions,
directed evolution experiments on GP64 have revealed that the E45K/T259A double mutant improved
up to eight-fold transduction of human airway epithelia [58]. The SVNs’ transduction and resistance
to serum can also be chemically enhanced by treatment with polymers such as polyethylene glycol
(PEG) or polyethylenimine (PEI) [59–62]. However, PEG and PEI coating strategies are not free of risks.
For instance, a high degree of PEG coating (PEGylation) significantly reduces baculovirus titer [62].
Anti-PEG immunity [63] must be carefully considered in PEG-baculovirus formulations, and PEI could
be subject to similar problems [64]. Additionally, baculovirus high titer stocks have been shown to
have a reduced shelf life due to the formation of non-functional aggregates [65]. Given that both PEG
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and PEI increase the baculovirus molecular weight, further studies are required to address the impact
of these coating strategies on the formation of non-functional aggregates.
Table 1. Known challenges to baculovirus administration in vivo and a summary of strategies to
overcome them.
Baculovirus in Vivo Delivery Challenges Approaches to Overcome Issue
Narrow tropism
(e.g., target cells or tissue are not efficiently transduced)
Pseudotyping can be used to change or expand cell tropism:
• Vescicular stomatitis virus glycoprotein, VSV-G [19,66–68];
• Rabies virus glyprotein RVG [69];
• Cell-type specific peptides [70];
• Thogoto and Dori virus envelope proteins [71];
• Gp64 mutants [58].
Serum complement-mediated inactivation
Baculovirus is inactivated by human serum complement-cascade
Pseudotyping with complement shielding factors can enhance viral
stability in the bloodstream:
• Decay accelerating factor (DAF) [72];
• Chimeric DAF fused to complement regulatory factors [73].
Chemical modifications have been reported to enhance serum
resistance:
• Polyethylene glycol (PEG) coating [62];
• Polyethylenimine (PEI) coating [60,61].
Intracellular immune response inactivation
Baculovirus efficiently reaches target cells but is rapidly inactivated
and silenced by intracellular immune response pathways.
Histone deacetylases (HDACs) inhibitors can be used ex vivo to
counteract silencing. Due to broad spectra and high toxicity they
cannot be used systemically:
•Valproic acid (VPA) or sodium butyrate (NaBu) [74,75].
Genetically encoded intracellular immune suppression strategies
increase transgene expression:
• Ablation of STING, TBK1, IRF3, or IPS-1 [76];
• RNA interference of RIPK1 [77];
• Viral proteins with intracellular immuno-suppressive activity
(NS3/4a protease from Hepatitis C virus) [76].
Although the baculovirus ably transduces a wide range of mammalian cell lines with high
efficiency, some cell types seem to be completely refractory to AcMNPV transduction. To overcome this
limitation, much effort has been put into engineering the baculoviral envelope. BVs displaying intact
or truncated versions of the VSV envelope glycoprotein (VSV-G) are particularly popular [19,66,67].
Because desired peptides or proteins can be easily displayed on the viral membrane by direct fusion
to full-length or shortened versions of GP64, various protein motifs have also been explored to
achieve cell-specific targeting [78–81]. Pseudotyping of glycoproteins from naturally occurring viruses
can be included, granting even broader or cell-type specific tropism. In addition to VSV-G [68],
baculoviruses displaying other molecules have been successfully engineered. These include rabies
virus glycoprotein (RVG) [69] and glycoproteins from Thogoto or Dhori viruses [71] with cell type
dependent improvements on transduction efficiency. Additionally, baculovirus tropism can be altered
by introducing cell-specific peptides extensively tested for redirecting AAVs or lentiviral vectors [70].
Accumulating evidence has suggested that baculoviral genomes could be rapidly inactivated
and silenced by innate intracellular immune response pathways [76,77]. This phenotype, again,
cell type dependent, has been traditionally counteracted by the addition of small molecule inhibitors
of histone deacetylases (HDACs) including valproic acid (VPA) or sodium butyrate (NaBu) [74,75].
While these molecules have shown remarkable improvement of transgene expression in most cell
lines, HDAC inhibitors were toxic and could not be administered in vivo. The mechanisms of
baculoviral transgene silencing in mammalian cells were likely to be mediated by pattern recognizing
receptors (PRRs) and their downstream signaling effectors, including stimulator of interferon genes
(STING) [76] and cells defective for the immune-response pathway components such as STING,
TBK1, IRF3, or IPS-1 have shown higher baculovirus transgene expression [76]. Interestingly, a short
hairpin library study identified RIPK1 as a target, the ablation of which did not result in detectable
cytotoxicity, while enhancing baculovirus mediated transgene expression [77], suggesting that transient
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intracellular immune response modulation, ideally by heterologous modalities hardwired into the
baculoviral genome, could be a viable strategy to further improve BV mediated transduction.
Baculoviral vectors lack pre-existing immune response in humans [21], however, they have
not naturally evolved to escape the innate immune response mediated by the complement cascade
system [82]. Early studies showed that BVs were rapidly inactivated by human serum complement
and that inhibition of serum complement restored their transduction potential [83]. Towards systemic
baculovirus delivery for in vivo applications, successful strategies have been deployed to counteract
complement-mediated inactivation through complement shielding pseudotyping. For instance,
decay-accelerating factor (DAF) [72] or DAF fused to complement regulatory proteins [73] have been
successfully displayed on the viral surface to shield it from serum complement together with a variety
of other strategies which have been authoritatively reviewed previously [84].
6. From MultiBac to Synthetic Virus-Derived Nanosystems (SVNs)
During viral production, overamplification of recombinant baculovirus is avoided to prevent
spontaneous recombination and formation of defective interfering particles (DIPs) [19,85]. Unlike AAVs
or lentiviral vectors, baculovirus expression vectors have not been extensively modified and the
AcMNPV genome used in all BVs has remained substantially identical. Because BVs have been
extensively used and studied to produce recombinant proteins and protein complexes, the functions of
most of the 156 genes of wild-type AcMNPV have been characterized or inferred by homology [22].
By studying baculoviral genomes evolutionary conservation, combined with literature-based
knowledge, we previously ranked ORFs based on their likeliness to be deleted without affecting
viral production [86]. Building on this knowledge, design and testing of synthetic MultiBac genomes
(SynBac) [28] should result in vectors with reduced size, improved stability, and better suited for
indefinite amplification and faithful gene transfer into mammalian cells.
In order to tackle current challenges, minimization, design, and rapid re-adaptation of synthetic
baculovirus genomes for different target cells/administration routes are crucial features for their
successful implementation as in vivo gene delivery vectors. Through extensive and rational
baculovirus engineering, it should be possible to gradually move from AcMNPVs to synthetic
virus-derived nanosystems (SVNs), while preserving transduction efficiency and high viral production
titers and simultaneously implementing molecular strategies to circumvent known roadblocks to BV
mediated in vivo delivery. Initial steps in simplifying baculoviral genome engineering have been
implemented in the MultiBac system [87]. Customized MultiBac genomes have been developed
hosting diverse modules hardwired in the viral backbone. For instance, MultiBac genomes have been
successfully functionalized adding fluorescent probes to monitor viral titers [87], pyrolysyl tRNA/tRNA
synthetase for genetic code expansion [88], or mammalian glycosylases and others [89] (Figure 8).
The ongoing development of synthetic minimal baculoviral genomes (SynBac) should maximize
cargo to backbone capacity and stability, facilitating the implementation of modular functions depending
on the final application. Of note, preliminary tests with SynBac1.0, in which a 10 kb fragment (7.6% of
the wild-type genome) was ablated, have already resulted in a synthetic virus with improved genome
stability over prolonged passaging and high-level protein production [28]. Among the advantages
of synthetic minimized genomes is the potential to combine several features into a single, optimized
backbone. For instance, in gene editing applications, modules encoding Cas9 or BE/PE2 machinery,
could be directly incorporated into the synthetic genome, rather than being provided separately
through Tn7 recombination (Figure 8). In the same vein, for in vivo applications, several genetically
encoded strategies such as altered pseudotyping [68,71] or serum complement shielding [72] could be
combined into SVNs with enhanced tropisms and activity in living organisms.
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Figure 8. Evolution of baculoviral genomes building up from MultiBac technology. Since its first
implementation, MultiBac allowed easy baculoviral genomes and hosting of different Built-in reporter or
pseudo-typing components have contributed to enhance virus production (EmbacY) and transduction
in mammalian cells (MultiBacMam). In addition to the incorporation of CRISPR components on
synthetic and minimized genomes (SynBac), genetically encoded strategies for innate immune response
shielding (RNA interference or protease-based), and decay accelerating factor (DAF) pseudo-typing,
will enable in vivo systemic administration into living organisms.
The range of interventions to optimize in vivo SVNs’ potential, could also span genetically encoded
strategies to tame intracellular pathways which lead to baculovirus inactivation. These could include
RNA interference against known mediators of viral inactivation [76,77] or the inclusion of ortholog
viral proteases [76] (e.g., NS3/4a protease from Hepatitis C virus) with known immuno-suppressing
activities to enhance transgene expression and gene editing efficiency (Figure 8).
7. Conclusions and Outlook
Proof-of-concept experiments using MultiBac confirmed that baculoviral vectors have the potential
to become a powerful platform to deliver elaborate CRISPR machineries in mammalian cells granting
high transduction efficiency and enhanced safety, situated at the boundary between viral and nonviral
delivery systems and combining advantages of both. If outfitted with HITI for NHEJ-mediated precise
gene editing, baculovirus holds the unique potential of being able to carry all-in-one vectors which are
currently impossible to assemble or deliver with alternative viral vectors. Furthermore, in virtue of
their extended cargo capacity, BVs, and in particular, the more advanced SVNs, hold the potential to
overcome many of the limitations imposed by AAVs or lentiviral vectors, further expanding the range
of gene editing intervention to large transgene docking and whole gene replacement.
Despite the absence of pre-existing immunity, baculovirus, in general, is still subject to innate
immunity inactivation. Serum complement rapidly inactivates baculoviral particles, whereas,
at the cellular level, PRRs recognize and inactivate baculoviruses through different sets of
recognition/effector pathways. Additionally, baculoviral glycoprotein (gp64) does not have a wide
mammalian cell tropism and it is known that baculoviral genomes cannot be amplified indefinitely
due to spontaneous recombination events, increasing the cost of manufacturing high-quality virions,
albeit this can conceivably be overcome by engineering towards enhanced stability. Although a whole
range of applications is already possible using multigene assembly technologies such as MultiBac,
a further step in vector engineering must be undertaken to design BVs which can reliably be used as
in vivo delivery vectors. To tackle these challenges, with the aim of generating optimal vectors for
gene editing in vivo, a gradual process, started with MultiBac genomes engineering, aims at designing
and implementing synthetic viral genomes with reduced DNA burden and complexity, which can be
further functionalized with multiple genetically encoded components to meet the needs for industrially
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manufactured in vivo delivery vectors for a variety of applications. These synthetic virus-derived
nanoparticles (SVNs) should ideally combine enhanced stability, selective tropism, and superior
activity, with shielding from the innate immune system through ”stealth” envelopes, and the capacity
to deploy intracellular immune-suppressing components and modalities.
We anticipate that SVNs could make for an excellent all-in-one CRISPR delivery platform which
could be iteratively modified towards large DNA precision docking and bona fide genome engineering,
capable of erasing and rewriting large sections of target genomes. Unlike currently available CRISPR
delivery systems, SVNs would enable scientists to engineer the delivery vector to meet their needs,
rather than adapting the gene editing approach to the delivery system, while offering an unprecedented
range of gene editing interventions ex vivo and in vivo in virtue of virtually little to no DNA
cargo constraints.
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